Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

Date: April 19, 2018
Pages: 65
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G7A3D62774BEN
Leaflet:

Download PDF Leaflet

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA Key Recent Developments

Mar 05,2018: Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
Dec 04,2017: Grifols Misterium Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation
Nov 22,2017: Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components
Nov 02,2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million
Aug 22,2017: Grifols Phocus Rx Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Grifols SA - Key Facts
Grifols SA - Key Employees
Grifols SA - Key Employee Biographies
Grifols SA - Major Products and Services
Grifols SA - History
Grifols SA - Company Statement
Grifols SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Grifols SA - Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Bioscience
Overview
Performance
Key Stats
Business Segment: Diagnostic
Overview
Performance
Business Segment: Hospital
Overview
Performance
Business Segment: Other Segment
Overview
Performance
Geographical Segment: European Union
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA - Corporate Strategy
Grifols SA - SWOT Analysis
SWOT Analysis - Overview
Grifols SA - Strengths
Grifols SA - Weaknesses
Grifols SA - Opportunities
Grifols SA - Threats
Grifols SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Grifols SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 05, 2018: Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
Dec 04, 2017: Grifols Misterium Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation
Nov 22, 2017: Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components
Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million
Aug 22, 2017: Grifols Phocus Rx Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces
Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions
Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation's John W. Walsh Research Fund
Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples
Jun 05, 2017: Grifols' physiological saline solution produced in its Murcia facility receives U.S. FDA approval
May 03, 2017: Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont.1)
Grifols SA, Annual Ratios (Cont.2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Grifols SA, Performance Chart (2013 - 2017)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Oryzon Genomics SA
HemaCare Corp
CSL Ltd
Abeona Therapeutics Inc
AB-Biotics SA
Skip to top


Ask Your Question

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: